BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 26315810)

  • 21. Ticagrelor vs clopidogrel followed by ticagrelor re-loading in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: A randomized, pharmacodynamic comparison.
    Alexopoulos D; Kontoprias K; Gkizas V; Karanikas S; Ziakas A; Barampoutis N; Tsigkas G; Koutsogiannis N; Davlouros P; Patsilinakos S; Karvounis H; Hahalis G; Xanthopoulou I
    Platelets; 2016 Jul; 27(5):420-6. PubMed ID: 26763727
    [TBL] [Abstract][Full Text] [Related]  

  • 22. COMPARison of pre-hospital CRUSHed vs. uncrushed Prasugrel tablets in patients with STEMI undergoing primary percutaneous coronary interventions: Rationale and design of the COMPARE CRUSH trial.
    Vlachojannis GJ; Vogel RF; Wilschut JM; Lemmert ME; Delewi R; Diletti R; van Vliet R; van der Waarden N; Nuis RJ; Paradies V; Alexopoulos D; Zijlstra F; Montalescot G; Angiolillo DJ; Krucoff MW; Van Mieghem NM; Smits PC
    Am Heart J; 2020 Jun; 224():10-16. PubMed ID: 32272255
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients With ST-Segment-Elevation Myocardial Infarction: Primary Results of the FABOLUS-FASTER Trial.
    Gargiulo G; Esposito G; Avvedimento M; Nagler M; Minuz P; Campo G; Gragnano F; Manavifar N; Piccolo R; Tebaldi M; Cirillo P; Hunziker L; Vranckx P; Leonardi S; Heg D; Windecker S; Valgimigli M
    Circulation; 2020 Aug; 142(5):441-454. PubMed ID: 32795098
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An open-label, randomized bioavailability study with alternative methods of administration of crushed ticagrelor tablets in healthy volunteers.
    Teng R; Carlson G; Hsia J
    Int J Clin Pharmacol Ther; 2015 Feb; 53(2):182-9. PubMed ID: 25500486
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Crushed/chewed administration of potent P2Y
    Guo C; Zhao JR; Chen MJ; Zhang Y; Wu RY; Li QQ; Zhao H; Wei J
    Platelets; 2022 Jul; 33(5):679-686. PubMed ID: 34472997
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of TIcagrelor administered through a nasogastric tube to COMAtose patients undergoing acute percutaneous coronary intervention: the TICOMA study.
    Ratcovich H; Sadjadieh G; Andersson HB; Frydland M; Wiberg S; Dridi NP; Kjaergaard J; Holmvang L
    EuroIntervention; 2017 Feb; 12(14):1782-1788. PubMed ID: 28216475
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics and pharmacodynamics of ticagrelor in subjects on hemodialysis and subjects with normal renal function.
    Teng R; Muldowney S; Zhao Y; Berg JK; Lu J; Khan ND
    Eur J Clin Pharmacol; 2018 Sep; 74(9):1141-1148. PubMed ID: 29850937
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Platelet inhibition with standard vs. lower maintenance dose of ticagrelor early after myocardial infarction (ELECTRA): a randomized, open-label, active-controlled pharmacodynamic and pharmacokinetic study.
    Kubica J; Adamski P; Buszko K; Barańska M; Sikora J; Marszałł MP; Sobczak P; Sikora A; Kuliczkowski W; Fabiszak T; Kubica A; Jilma B; Alexopoulos D; Navarese EP
    Eur Heart J Cardiovasc Pharmacother; 2019 Jul; 5(3):139-148. PubMed ID: 30689800
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Angiographic outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes).
    Kunadian V; James SK; Wojdyla DM; Zorkun C; Wu J; Storey RF; Steg PG; Katus H; Emanuelsson H; Horrow J; Maya J; Wallentin L; Harrington RA; Gibson CM
    JACC Cardiovasc Interv; 2013 Jul; 6(7):671-83. PubMed ID: 23866179
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of Pre-Hospital Ticagrelor During the First 24 h After Primary Percutaneous Coronary Intervention in Patients With ST-Segment Elevation Myocardial Infarction: The ATLANTIC-H²⁴ Analysis.
    Montalescot G; van 't Hof AW; Bolognese L; Cantor WJ; Cequier A; Chettibi M; Collet JP; Goodman SG; Hammett CJ; Huber K; Janzon M; Lapostolle F; Lassen JF; Licour M; Merkely B; Salhi N; Silvain J; Storey RF; Ten Berg JM; Tsatsaris A; Zeymer U; Vicaut E; Hamm CW;
    JACC Cardiovasc Interv; 2016 Apr; 9(7):646-56. PubMed ID: 26952907
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of opioids on P2Y12 receptor inhibition in patients with ST-elevation myocardial infarction who are pre-treated with crushed ticagrelor: Opioids aNd crushed Ticagrelor In Myocardial infarction Evaluation (ON-TIME 3) trial.
    Tavenier AH; Hermanides RS; Ottervanger JP; Tolsma R; van Beurden A; Slingerland RJ; Ter Horst PGJ; Gosselink ATM; Dambrink JE; van Leeuwen MAH; Roolvink V; Kedhi E; Klungel OH; Belitser SV; Angiolillo DJ; Pustjens T; Rasoul S; Gho B; Stein M; Ruiters L; van 't Hof AWJ
    Eur Heart J Cardiovasc Pharmacother; 2022 Jan; 8(1):4-12. PubMed ID: 32730628
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ambulance or in-catheterization laboratory administration of ticagrelor for primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: rationale and design of the randomized, double-blind Administration of Ticagrelor in the cath Lab or in the Ambulance for New ST elevation myocardial Infarction to open the Coronary artery (ATLANTIC) study.
    Montalescot G; Lassen JF; Hamm CW; Lapostolle F; Silvain J; ten Berg JM; Cantor WJ; Goodman SG; Licour M; Tsatsaris A; van't Hof AW
    Am Heart J; 2013 Apr; 165(4):515-22. PubMed ID: 23537967
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development Strategy and Relative Bioavailability of a Pediatric Tablet Formulation of Ticagrelor.
    Niazi M; Wissmar J; Berggren AR; Karlsson C; Johanson P
    Clin Drug Investig; 2019 Aug; 39(8):765-773. PubMed ID: 31140114
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of double (360 mg) ticagrelor loading dose with standard (60 mg) prasugrel loading dose in ST-elevation myocardial infarction patients: the Rapid Activity of Platelet Inhibitor Drugs (RAPID) primary PCI 2 study.
    Parodi G; Bellandi B; Valenti R; Migliorini A; Marcucci R; Carrabba N; Giurlani L; Gensini GF; Abbate R; Antoniucci D
    Am Heart J; 2014 Jun; 167(6):909-14. PubMed ID: 24890542
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antiplatelet effect of ticagrelor compared to tirofiban in non-ST-segment elevation ACS patients undergoing PCI. The result of the TE-CLOT trial.
    Kim JS; Han DC; Jeong YH; Park DW; Sohn CB; Hwang KW; Lee SH; Choi JH; Chon MK; Lee SY; Hwang J; Kim IS; Lee SM; Han J; Noh M; Kim CH; Chun KJ; Park YH; Kim JH
    Thromb Haemost; 2016 Jan; 115(1):213-21. PubMed ID: 26581884
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cangrelor in combination with ticagrelor provides consistent and potent P2Y12-inhibition during and after primary percutaneous coronary intervention in real-world patients with ST-segment-elevation myocardial infarction.
    Mohammad MA; Andell P; Koul S; James S; Scherstén F; Götberg M; Erlinge D
    Platelets; 2017 Jun; 28(4):414-416. PubMed ID: 27885888
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and efficacy of ticagrelor and clopidogrel in primary percutaneous coronary intervention.
    Velders MA; Abtan J; Angiolillo DJ; Ardissino D; Harrington RA; Hellkamp A; Himmelmann A; Husted S; Katus HA; Meier B; Schulte PJ; Storey RF; Wallentin L; Gabriel Steg P; James SK;
    Heart; 2016 Apr; 102(8):617-25. PubMed ID: 26848185
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prehospital ticagrelor in ST-segment elevation myocardial infarction.
    Montalescot G; van 't Hof AW; Lapostolle F; Silvain J; Lassen JF; Bolognese L; Cantor WJ; Cequier A; Chettibi M; Goodman SG; Hammett CJ; Huber K; Janzon M; Merkely B; Storey RF; Zeymer U; Stibbe O; Ecollan P; Heutz WM; Swahn E; Collet JP; Willems FF; Baradat C; Licour M; Tsatsaris A; Vicaut E; Hamm CW;
    N Engl J Med; 2014 Sep; 371(11):1016-27. PubMed ID: 25175921
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics and tolerability of single and multiple doses of ticagrelor in healthy Chinese subjects: an open-label, sequential, two-cohort, single-centre study.
    Li H; Butler K; Yang L; Yang Z; Teng R
    Clin Drug Investig; 2012 Feb; 32(2):87-97. PubMed ID: 22168538
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Double versus standard loading dose of ticagrelor: onset of antiplatelet action in patients with STEMI undergoing primary PCI.
    Alexopoulos D; Gkizas V; Patsilinakos S; Xanthopoulou I; Angelidis C; Anthopoulos P; Makris G; Perperis A; Karanikas S; Koutsogiannis N; Davlouros P; Deftereos S; Chiladakis J; Hahalis G
    J Am Coll Cardiol; 2013 Sep; 62(10):940-1. PubMed ID: 23747780
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.